ScoreWhy is Xvivo Perfusion AB ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 35.19%
2
With a growth in Operating Profit of 34.21%, the company declared Very Positive results in Mar 26
- OPERATING CASH FLOW(Y) Highest at SEK 181.66 MM
- PRE-TAX PROFIT(Q) Highest at SEK 42.83 MM
- NET PROFIT(Q) Highest at SEK 36.3 MM
3
With ROE of 1.32%, it has a very expensive valuation with a 2.80 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -8.11%, its profits have fallen by -85.5%
4
Underperformed the market in the last 1 year
- Even though the market (OMX Stockholm 30) has generated returns of 30.13% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -8.11% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Xvivo Perfusion AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xvivo Perfusion AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xvivo Perfusion AB
-8.11%
24.07
58.09%
OMX Stockholm 30
30.13%
1.89
15.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
35.19%
EBIT Growth (5y)
47.44%
EBIT to Interest (avg)
3.87
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.36
Tax Ratio
12.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.93%
ROE (avg)
3.50%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
212
Industry P/E
Price to Book Value
2.80
EV to EBIT
60.58
EV to EBITDA
34.52
EV to Capital Employed
3.07
EV to Sales
6.94
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.07%
ROE (Latest)
1.32%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK 181.66 MM
PRE-TAX PROFIT(Q)
Highest at SEK 42.83 MM
NET PROFIT(Q)
Highest at SEK 36.3 MM
NET SALES(Q)
Highest at SEK 240.96 MM
EPS(Q)
Highest at SEK 1.15
-4What is not working for the Company
NET PROFIT(9M)
At SEK 72.2 MM has Grown at -45.86%
Here's what is working for Xvivo Perfusion AB
Pre-Tax Profit
At SEK 42.83 MM has Grown at 494.72%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (SEK MM)
Net Profit
At SEK 36.3 MM has Grown at 494.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (SEK MM)
Operating Cash Flow
Highest at SEK 181.66 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Pre-Tax Profit
Highest at SEK 42.83 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (SEK MM)
Net Profit
Highest at SEK 36.3 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (SEK MM)
Net Sales
Highest at SEK 240.96 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
EPS
Highest at SEK 1.15
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (SEK)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
